UMN Pharma Of Japan To Start Phase I/II Trials For Avian Flu Vaccine
This article was originally published in PharmAsia News
Executive Summary
Akita, Japan-based UMN Pharma, will start Phase I/II trials for avian flu vaccine UMN-501 in mid-June. Unlike current flu vaccines derived from embryonated chicken eggs, UMN-501 is derived from a recombinant protein, which will enable production of large quantities of vaccine in a short time period. UMN Pharma acquired an exclusive license to manufacture and sell recombinant protein-based influenza vaccines in Japan from the U.S. firm Protein Sciences Corporation. (Click here for more - Japanese language